港股異動丨興科蓉醫藥(6833.HK)大漲近17%創新高 配售1.6億股淨籌約1.95億港元
格隆匯12月8日丨興科蓉醫藥(6833.HK)大幅拉昇漲近17%,高見1.88港元再創歷史新高價,總市值達35億港元。公司擬配售1.6億股,淨籌約1.95億港元。所得款項包括但不限於收購醫療美容機構或投資醫療美容項目及開發新醫療美容產品等項目。董事認為,配售事項所得款項可讓集團把握醫療美容產品的市場機遇,並可自設中心,以逐步開發、生產及銷售醫療美容產品。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.